



Bacteriophages and Other Alternative Antimicrobials to Combat Multidrug Resistance

Guest Editors:

Dr. Andrey A. Filippov

Wound Infections Department,
Bacterial Diseases Branch, Walter
Reed Army Institute of Research,
Silver Spring, MD, USA

Dr. Mikeljon P. Nikolich

Wound Infections Department,
Bacterial Diseases Branch, Walter
Reed Army Institute of Research,
Silver Spring, MD, USA

Deadline for manuscript
submissions:

30 June 2024

Message from the Guest Editors

This Special Issue is focused on isolation, synthesis, engineering, characterization, preclinical testing and clinical use of any novel antibacterials that are alternative to classical antibiotics. Articles covering comparisons and combinations of new drugs and standard-of-care antibiotics are also welcome. Additional topics of interest will include safety, stability and immunogenicity of novel drugs, improved formulations, manufacturing, storage, delivery, regulatory aspects, the development of bacterial resistance and ways to overcome it. Both original papers and review articles will be considered for publication in this Special Issue of *Antibiotics*.

Keywords

- multidrug resistance
- alternative antibacterials
- bacteriophage therapy
- phage-antibiotic synergy
- phage lysins
- small molecule drugs
- monoclonal antibodies
- antivirulence drugs
- pharmacokinetics and pharmacodynamics
- resistance to novel drugs





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1
(*General Pharmacology, Toxicology and Pharmaceutics*)

Contact Us

Antibiotics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)